Nusinersen: The First Approval for Spinal Muscular Atrophy

Experts shed light on the data behind the first FDA approval for spinal muscular atrophy (SMA), nusinersen, and consider what was learned through its approval.

Neurology,NeurologyLive,NeurologyLive Peer Exchange,Nancy L. Kuntz,Claudia Chiriboga,Basil Darras,Elizabeth Kichula,SMA,Spinal Muscular Atrophy,Nusinersen,Neuromuscular Disorder,Neuromuscular,Neuromuscular Disorders,